Marc B. Garnick
Professor of Medicine
Beth Israel Deaconess Medical Center
United States of America
Dr. Marc Garnick is Clinical Professor of Medicine at Harvard Medical School and internationally renowned expert in medical oncology and urologic cancer. He has dedicated his career to helping his patients and their families understand the complex medical issues when faced with determining appropriate treatment choices and the development of new therapies for the treatment of prostate cancer. To further research in prostate cancer, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research.
Garnick MB. Possible confusion in names of new treatments for prostate cancer. New England Journal of Medicine. 2013 Jan 10;368(2):194-.
Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJ. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. InUrologic Oncology: Seminars and Original Investigations 2017 Mar 18. Elsevier.
Garnick MB. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.